Effects of sulfinpyrazone on retinae damage induced by experimental diabetes mellitus in rabbits

Pharmacological Research

Volumn 38, Issue 2, 1998, Pages 97-100

  Drago, F ^a   La Manna, C ^a   Emmi, I ^a   Marino, A ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Diabetes mellitus; Metabolism; Retina; Sulfinpyrazone

Indexed keywords

2 OXOGLUTARIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CITRIC ACID; GLUCOSE; LACTIC ACID; PYRUVIC ACID; SUCCINIC ACID; SULFINPYRAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RETINA INJURY; STREPTOZOCIN DIABETES; VASCULAR ENDOTHELIUM; ANIMAL; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; RETINA;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; MALE; RABBITS; RETINA; SULFINPYRAZONE;

EID: 0032129208     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0339     Document Type: Article

References (17)

1. 1. Leutenegger F, Michot F. Influence of sulfinpyrazone (Anturan) on thrombo-elastography. J Int Med Res 1978; 6: 133-8.
2. 2. Bouchier-Hayes D. Drugs in the treatment of tromboembolic diseases. Ir Med J 1983; 76: 101-7.
3. 3. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-9.
4. 4. Bergmeyer, HU, Bernt E, Schmidt F, Stork H. D-glucose. Determination with hexokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1974: 1196-201.
5. 5. Noll F. Enzymatic determination of lactate. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Weinheim: Verlag Chemie, 1984: 582-8.
6. 6. Czok R, Lamprecht W. Pyruvate, phosphoenolpyruvate and D-glycerate-2-phosphate. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1973: 1446-51.
7. 7. Benzi G, Arrigoni E, Pastoris O, Raimondo S, Dossena M, Fulle D, Tumminello MC, Villa RF. Drug interference on some biochemical parameters of rat cerebral cortex during post-ischaemic recovery. Arch Int Pharmacodyn Ther 1980; 247: 198-216.
8. 8. Lamprecht W., Trautschold I. Adenosine-5′-triphosphate. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1973: 2101-10.
9. 9. Jaworek D, Gruber W. Bergmeyer HU. Adenosine-5′-disphosphate and adenosine-5′monophosphate. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press, 1973: 2127-31.
10. 10. Evans G, Gent M. Effect of platelet suppressive drugs on arterial and venous thromboembolism. In: Evans G, ed. Platelet, Drugs and Thrombosis. Basel: Karger, 1975: 258-62.
11. 11. Margulies EH, White AM. Sulfinpyrazone: a pharmacological review. In: Goldberg ME, ed. Pharmacological and Biochemical Properties of Drug Substances, Vol. 2. Washington DC: Am Pharm Assoc, 1979: 255-78.
12. 12. McGregor MM (1979). Cardiovascular actions of sulfinpyrazone: basic and clinical research. Symposia Specialists. Bermuda: Hamilton, 1979: 342-54.
13. 13. Verry M, Panak E, Cazenave JP. Antiplatelet therapy in the prevention of ischaemic stroke. Nouv Rev Fr Hematol 1994; 36: 213-28.
14. 14. Barnett HJ, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238-48.
15. 15. Keyser A. Platelet aggregation inhibitors in neurology. Pharm World Sci 1993; 15: 243-51.
16. 16. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-24.
17. 17. He M, Kunze KL, Trager WF. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. Drug Metab Dispos 1995; 23: 659-63.